EA200600484A1 - Доставка физиологических агентов in situ при помощи гелей, включающих анионные полисахариды - Google Patents

Доставка физиологических агентов in situ при помощи гелей, включающих анионные полисахариды

Info

Publication number
EA200600484A1
EA200600484A1 EA200600484A EA200600484A EA200600484A1 EA 200600484 A1 EA200600484 A1 EA 200600484A1 EA 200600484 A EA200600484 A EA 200600484A EA 200600484 A EA200600484 A EA 200600484A EA 200600484 A1 EA200600484 A1 EA 200600484A1
Authority
EA
Eurasian Patent Office
Prior art keywords
situ
delivery
polysaccharides
anional
gels
Prior art date
Application number
EA200600484A
Other languages
English (en)
Other versions
EA010351B1 (ru
Inventor
Йавей Ни
Кеннет М. Йэйтс
Original Assignee
Делсайт Байотекнолоджиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Делсайт Байотекнолоджиз, Инк. filed Critical Делсайт Байотекнолоджиз, Инк.
Publication of EA200600484A1 publication Critical patent/EA200600484A1/ru
Publication of EA010351B1 publication Critical patent/EA010351B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к гелеобразующим композициям для доставки фармакологически активных веществ in situ в ткани, жидкости организма и слизистые оболочки животных в форме жидкостей, твердых веществ и порошков, которые содержат анионные полисахариды и, в частности, низшие метоксипектины в качестве гелеобразующих агентов, к способам получения и способам применения гелеобразующих композиций для доставки и пролонгированного высвобождения физиологически активного агента in situ и, в частности, вакцинных антигенов, в ткани и слизистые оболочки животного.
EA200600484A 2003-08-29 2004-05-24 Доставка физиологических агентов in situ при помощи гелей, включающих анионные полисахариды EA010351B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/652,622 US7494669B2 (en) 2001-02-28 2003-08-29 Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
PCT/US2004/016146 WO2005023176A2 (en) 2003-08-29 2004-05-24 Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides

Publications (2)

Publication Number Publication Date
EA200600484A1 true EA200600484A1 (ru) 2006-10-27
EA010351B1 EA010351B1 (ru) 2008-08-29

Family

ID=34273408

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600484A EA010351B1 (ru) 2003-08-29 2004-05-24 Доставка физиологических агентов in situ при помощи гелей, включающих анионные полисахариды

Country Status (9)

Country Link
US (1) US7494669B2 (ru)
EP (1) EP1663111A4 (ru)
JP (1) JP4765020B2 (ru)
KR (1) KR20060127841A (ru)
CN (1) CN1874679A (ru)
AU (1) AU2004270101A1 (ru)
CA (1) CA2537290C (ru)
EA (1) EA010351B1 (ru)
WO (1) WO2005023176A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7705135B2 (en) 1998-05-13 2010-04-27 Nanotherapeutics, Inc. Pharmaceutical compositions comprising aloe pectins, and methods for their production and use

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113730A1 (en) * 2003-11-24 2005-05-26 Sca Hygiene Products Ab Absorbent Article Containing A Skin Care Product
PE20060468A1 (es) * 2004-04-26 2006-07-06 Cp Kelco Aps Composicion dermoprotectora para controlar la alcalinidad de la piel que comprende polisacaridos de acido carboxilico
US20060106117A1 (en) * 2004-11-12 2006-05-18 Kimberly-Clark Worldwide, Inc. Compound and method for prevention and/or treatment of vaginal infections
US20060223765A1 (en) * 2005-03-30 2006-10-05 Kimberly-Clark Worldwide, Inc. Method for inhibiting and/or treating vaginal infection
US7786176B2 (en) 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
KR20080081175A (ko) * 2005-12-19 2008-09-08 코멘티스, 인코포레이티드 안구 투여를 위한 국소 메카밀라민 제형 및 그것의 사용
JP2010521215A (ja) * 2007-03-13 2010-06-24 バイオラインアールエックス リミテッド 組織の修復を促進する方法
CN103083642B (zh) * 2007-05-11 2015-11-18 芦荟研究实验室公司 用于皮肤增强的芦荟制剂
ES2625866T3 (es) 2007-11-27 2017-07-20 Algipharma As Uso de oligómeros de alginatos para combatir las biopelículas
JP2009209086A (ja) * 2008-03-04 2009-09-17 Masami Moriyama 粘膜投与型ワクチン
US7833829B2 (en) * 2008-10-28 2010-11-16 Honeywell International Inc. MEMS devices and methods of assembling micro electromechanical systems (MEMS)
GB2483203B (en) 2009-06-03 2013-06-19 Algipharma As Treatment of acinetobacter with alginate oligomers and antibiotics
GB0909529D0 (en) 2009-06-03 2009-07-15 Algipharma Ipr As Alginate oligomers for the inhibition of microbial adherence to surfaces
GB0909557D0 (en) 2009-06-03 2009-07-15 Algipharma Ipr As Anti-microbial alginate oligomers
JP2011057605A (ja) * 2009-09-09 2011-03-24 Masami Moriyama 粘膜投与型ワクチン
CN101703490B (zh) * 2009-11-13 2013-08-07 杭州师范大学 聚多糖/无机纳米粒子杂化微纳米载药胶囊
US8852645B2 (en) 2009-11-19 2014-10-07 The Board Of Trustees Of The University Of Illinois Self-assembled toroidal-spiral particles and manufacture and uses thereof
WO2011079260A2 (en) * 2009-12-23 2011-06-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
JP5996837B2 (ja) * 2010-05-28 2016-09-21 小林製薬株式会社 インフルエンザウイルスの感染抑制剤
FR2960775A1 (fr) * 2010-06-07 2011-12-09 Ethypharm Sa Microgranules resistants au detournement
ITVR20100140A1 (it) * 2010-07-13 2012-01-14 Eurocoating S P A Materiale composito formato da pectina e da calcio fosfato e metodo per la sua realizzazione
CN103209684A (zh) 2010-09-13 2013-07-17 贝夫-厄克斯股份有限公司 包含异味掩蔽剂的含水药物递送系统
CN103648587B (zh) * 2011-04-18 2021-09-17 乔治亚大学研究基金公司 疫苗递送方法
GB2490516A (en) * 2011-05-03 2012-11-07 Systagenix Wound Man Ip Co Bv Polysaccharide mould for wound treatment
GB201116010D0 (en) 2011-09-15 2011-10-26 Algipharma As Use of alginate oligomers to enhance the effects of antifungal agents
WO2013076305A1 (en) 2011-11-25 2013-05-30 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system
CN102429862B (zh) * 2011-11-29 2013-05-01 江苏德达医药科技有限公司 一种聚维酮碘眼用缓释滴眼液
GB201322777D0 (en) 2013-12-20 2014-02-05 Algipharma As Use of alginate oligomers as blood anticoagulants
PT3212204T (pt) 2014-10-28 2019-08-07 Biovotec As Partículas de membrana de ovos micronizados e uso dado para promover a cura de feridas
US20160158174A1 (en) * 2014-12-09 2016-06-09 Intercontinental Great Brands Llc Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients
EP3034070A1 (en) * 2014-12-18 2016-06-22 Omya International AG Method for the production of a pharmaceutical delivery system
KR102562736B1 (ko) * 2015-01-30 2023-08-03 닛산 가가쿠 가부시키가이샤 혈관 평활근 세포의 배양 방법
KR101777910B1 (ko) * 2015-04-30 2017-09-13 주식회사 제네웰 만성창상 치료용 조성물, 이의 제조방법 및 이를 이용한 만성창상 치료용 드레싱재
US11045578B2 (en) 2015-06-24 2021-06-29 Biovotec As Tissue engineering scaffolds comprising particulate egg shell membrane
MX2018002419A (es) 2015-08-28 2018-11-29 Ology Bioservices Inc Vacuna de norovirus.
GB201517639D0 (en) 2015-10-06 2015-11-18 Algipharma As Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
GB201519923D0 (en) 2015-11-11 2015-12-23 Biovotec Dac And Biovotec As Dry biocompatible disintegrateable films for delivering particulate egg shell membrane to a wound
WO2017151651A1 (en) * 2016-02-29 2017-09-08 Belmont University Pharmaceutical in situ gelling compositions
GB201618291D0 (en) 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
US10912858B2 (en) * 2017-05-01 2021-02-09 The Brigham And Women's Hospital, Inc. Pectin-carboxymethylcellulose mesothelial sealants and protectants
WO2019014194A1 (en) 2017-07-11 2019-01-17 DuPont Nutrition USA, Inc. PROCESS FOR PREPARING STABLE COLOR PREPARATION OF ALKALINE METAL SALT OF MAGNESIUM CHLOROPHYLLINE OR ALKALINE-EARTH METAL SALT FROM NATURAL CHLOROPHYLLE SOURCES
WO2019072877A1 (en) 2017-10-10 2019-04-18 Capsugel Belgium Nv GETTING MULTIPARTICULAR COMPOSITIONS
CA3079695A1 (en) * 2017-11-08 2019-05-16 Pasquale DEL GAUDIO In situ gelifying powder
EP3556398A1 (en) 2018-04-16 2019-10-23 Croda Denmark A/S Phytates for use as a biomolecules delivery or adsorption system
GB201908639D0 (en) 2019-06-17 2019-07-31 Algipharma Ipr As Use of alginate oligomers in the anticoagulation therapy of subjects at risk of blood clots which have an abnormally dense microstructure
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
CN114146169B (zh) * 2021-12-28 2023-08-25 佛山市正典生物技术有限公司 鸡球虫喷滴免疫用载体组合物及使用方法和鸡球虫喷滴免疫组合物
JPWO2024004159A1 (ru) * 2022-06-30 2024-01-04

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2629665A (en) * 1951-10-31 1953-02-24 James B Gordon Dietetic food product and method of preparing the same
US3622559A (en) 1967-11-01 1971-11-23 Sunkist Growers Inc Method for producing pectins having high resistance to breakage and high capability for gelling in the presence of calcium
US3946110A (en) * 1974-05-30 1976-03-23 Peter, Strong Research And Development Company, Inc. Medicinal compositions and methods of preparing the same
US3982003A (en) 1974-09-04 1976-09-21 Mars Limited Gelling and thickening agents
US4016351A (en) 1976-02-04 1977-04-05 Eschinasi Emile H Pectic substances with varying methoxyl content and process therefor
HU179474B (en) * 1978-02-24 1982-10-28 Laszlo Gyarmati Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material
US4305933A (en) 1980-03-10 1981-12-15 Wiczer Sol B Thickened gelatinous edible alcoholic medicated carrier
JPS607965B2 (ja) * 1980-08-07 1985-02-28 帝人株式会社 鼻腔粘膜投与用粉剤の製造法
US4497838A (en) 1982-02-17 1985-02-05 Tropicana Products, Inc. Process for the production of useful products from orange peel
US4917890A (en) * 1985-06-28 1990-04-17 Carrington Laboratories, Inc. Processes for preparation of aloe products, products produced thereby and compositions thereof
US5443830A (en) 1982-05-07 1995-08-22 Carrington Laboratories, Inc. Drink containing mucilaginous polysaccharides and its preparation
US5308838A (en) 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
US5118673A (en) 1982-05-07 1992-06-02 Carrington Laboratories, Inc. Uses of aloe products
US5106616A (en) 1988-01-14 1992-04-21 Carrington Laboratories, Inc. Administration of acemannan
US4966892A (en) 1982-05-07 1990-10-30 Carrington Laboratories, Inc. Processes for preparation of aloe products products produced thereby and compositions thereof
US4735935A (en) 1985-12-17 1988-04-05 Carrington Laboratories, Inc. Process for preparation of aloe products products, produced thereby and compositions thereof
US4851224A (en) 1986-06-05 1989-07-25 Carrington Laboratories, Inc. Process for preparation of aloe products
US5656587A (en) 1982-09-24 1997-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
US4500510A (en) * 1982-09-29 1985-02-19 Aquarium Pharmaceuticals, Inc. Damaged fish tissue treating method and composition containing Aloe vera extract
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
EP0188040B1 (en) * 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
US4959214A (en) 1985-06-28 1990-09-25 Carrington Laboratories Inc. Processes for preparation of aloe products products produced thereby and compositions thereof
US4957907A (en) 1985-06-28 1990-09-18 Carrington Laboratories Inc. Process for preparation of aloe products
US4847091A (en) * 1985-11-29 1989-07-11 Fisons Plc Pharmaceutical composition including sodium cromoglycate
DE3601132A1 (de) 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
DE3601923A1 (de) 1986-01-23 1987-07-30 Behringwerke Ag Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung
US5552528A (en) 1986-03-03 1996-09-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bovine b-endothelial cell growth factor
US4725438A (en) * 1986-05-29 1988-02-16 Leazer Billie S Aloe vera ointment
FR2600250B1 (fr) * 1986-06-23 1989-11-24 Bio Serae Procede pour conditionner une composition antibacterienne et composition antibacterienne conditionnee
US5288500A (en) * 1987-03-13 1994-02-22 Benzon Pharma A/S Oral composition containing particles comprising an active substance
FR2613936B1 (fr) 1987-04-17 1990-03-30 Centre Nat Rech Scient Application des resines constituees par des polymeres fonctionnels comme phase stationnaire en chromatographie d'affinite pour la purification des facteurs de croissance et procede de purification correspondant
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
DE3726797A1 (de) * 1987-08-12 1989-02-23 Bayer Ag Arzneimittel fuer den bereich der mundhoehle
US5059189A (en) 1987-09-08 1991-10-22 E. R. Squibb & Sons, Inc. Method of preparing adhesive dressings containing a pharmaceutically active ingredient
EP0308181A1 (en) * 1987-09-14 1989-03-22 Novo Nordisk A/S Trans-mucosal delivery formulations and a method for preparation thereof
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
DE3886880T2 (de) * 1987-10-15 1994-07-14 Syntex Inc Pulverförmige Zubereitungen zur intranasalen Verabreichung von Polypeptiden.
US5246708A (en) * 1987-10-28 1993-09-21 Pro-Neuron, Inc. Methods for promoting wound healing with deoxyribonucleosides
US5064650A (en) 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US5438076A (en) * 1988-05-03 1995-08-01 Perio Products, Ltd. Liquid polymer composition, and method of use
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
EP1016716A3 (en) 1989-01-31 2000-07-12 RUBIN, Jeffrey S Dna encoding a growth factor specific for epithelial cells
US5356630A (en) 1989-02-22 1994-10-18 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5191067A (en) 1989-04-27 1993-03-02 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
US5576288A (en) 1989-04-27 1996-11-19 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
US5130418A (en) 1989-05-02 1992-07-14 California Biotechnology Inc. Method to stabilize basic fibroblast growth factor
US5599551A (en) * 1989-06-06 1997-02-04 Kelly; Patrick D. Genital lubricants containing zinc as an anti-viral agent
US5208031A (en) * 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5545673A (en) * 1989-06-06 1996-08-13 Kelly; Patrick D. Method for reducing risk of infection by sexually transmitted viruses
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5422340A (en) 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
GB2237510B (en) * 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5512306A (en) * 1992-06-19 1996-04-30 Pharmica Ab Smoking substitute
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5284659A (en) * 1990-03-30 1994-02-08 Cherukuri Subraman R Encapsulated flavor with bioadhesive character in pressed mints and confections
US5217954A (en) 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
US5612211A (en) 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
US5714458A (en) 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
KR930006431B1 (ko) 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
DK0486862T3 (da) 1990-11-23 1996-06-24 American Cyanamid Co Kimær fibrolast-vækstfaktor
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5192802A (en) * 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
EP0547648B2 (en) 1991-11-14 1999-12-22 Dsm N.V. Improved process for the production of juices from fruits and vegetables
US6033712A (en) * 1994-05-13 2000-03-07 Ei Du Pont De Nemours And Company Gel production from plant matter
US5266318A (en) 1991-12-09 1993-11-30 Royale Renaissance, Inc. Skin therapeutic mixture containing cold-processsed aloe vera extract, with yellow sap and aloin removed
CA2125579C (en) 1991-12-17 2005-06-21 Richard C. Fuisz Ulcer prevention treatment composition and method
DE4201172C1 (en) 1992-01-17 1993-07-22 Alfatec-Pharma Gmbh, 6900 Heidelberg, De Pellets contg. Aloe vera extract - useful, e.g. as antiinflammatory of antibiotic agents, or for treating gastric ulcers
US5578307A (en) 1992-01-17 1996-11-26 Alfatec-Pharma Gmbh Shaped articles containing plant extract(s), in particular pellets, and their pharmaceutical or cosmetic use
AU659723B2 (en) 1992-02-14 1995-05-25 Kaken Pharmaceutical Co., Ltd. Remedy for airway diseases
US6197346B1 (en) * 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5703047A (en) 1992-09-21 1997-12-30 Board Of Regents, The University Of Texas System Methods and treatments for corneal healing with growth factors
US5589451A (en) 1992-09-21 1996-12-31 Board Of Regents, The University Of Texas System Methods and treaments for corneal healing with hepatocyte and keratinocyte growth factors
US5645827A (en) * 1992-09-30 1997-07-08 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
JP3266674B2 (ja) * 1992-11-19 2002-03-18 クミアイ化学工業株式会社 植物成長調整剤組成物
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US5435997A (en) * 1994-02-08 1995-07-25 Burns; Michael J. Topical agent and method for the treatment of pseudofolliculitis barbae
ES2225840T3 (es) 1994-03-08 2005-03-16 Osteosa Liquidation Trust Utilizacion de factores de crecimiento de fibroblasto para estimular el crecimiento oseo.
US5656598A (en) 1994-03-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Use of fibroblast growth factors to stimulate bone growth
US5503822A (en) * 1994-04-01 1996-04-02 Schulman; Jerome M. Medicated gel
US5571531A (en) 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5849327A (en) 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
JPH08198772A (ja) * 1994-11-25 1996-08-06 Kirin Brewery Co Ltd 顆粒球コロニー刺激因子含有粉末経鼻投与製剤
US5674495A (en) 1995-02-27 1997-10-07 Purdue Research Foundation Alginate-based vaccine compositions
CA2216919C (en) * 1995-03-28 2007-09-18 Fidia Advanced Biopolymers Srl Nanospheres comprising a biocompatible polysaccharide
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5753622A (en) 1995-05-10 1998-05-19 University Technologies International, Inc. Use of epidermal growth factor as a gastrointestinal therapeutic agent
US5693775A (en) 1995-05-12 1997-12-02 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
GB9514438D0 (en) * 1995-07-14 1995-09-13 Danisco Stabilisation process and an enzyme for use in such a process
US5900238A (en) * 1995-07-27 1999-05-04 Immunex Corporation Vaccine delivery system
US5902796A (en) * 1995-09-22 1999-05-11 Carrington Laboratories, Inc. Bioactive factors of aloe vera plants
US5656734A (en) 1995-10-30 1997-08-12 Systems Bio-Industries Methods for making pectin and pectocellulosic products
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US5760102A (en) * 1996-02-20 1998-06-02 Carrington Laboratories, Inc. Uses of denture adhesive containing aloe extract
DK0893992T3 (da) * 1996-04-16 2004-06-01 Novartis Consumer Health Sa Hurtigt sönderdelende oral doseringsform
AU732978B2 (en) * 1996-07-10 2001-05-03 Coloplast A/S Adhesive agent and use of such agent
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US5874094A (en) * 1997-08-05 1999-02-23 Costello; Jeremiah Cream formulation for topical application
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
CA2304958C (en) * 1997-09-26 2008-12-30 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
JP4234803B2 (ja) * 1997-10-27 2009-03-04 久光製薬株式会社 薬物放出速度が制御された医薬組成物
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
EP1035833B1 (en) * 1997-12-02 2005-08-31 Archimedes Development Limited Compositions for nasal administration
US6383495B1 (en) * 1997-12-08 2002-05-07 Council Of Scientific & Industrial Research Herbal formulation useful for treatment of skin disorders
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6290964B1 (en) * 1998-03-06 2001-09-18 Kathleen Shupe Antimicrobial agents isolated from aloe vera
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6313103B1 (en) * 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
FR2778566B1 (fr) * 1998-05-15 2001-07-20 Sep Tarral Preparations pectiques utilisables comme support de medicament
US6033651A (en) * 1998-06-10 2000-03-07 Revlon Consumer Products Corporation Gel cosmetic compositions
KR20000011247A (ko) * 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
US6063915A (en) * 1998-07-30 2000-05-16 Hercules Incorporated Carrageenan compositions and methods for their production
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
GB9828861D0 (en) * 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE60030418T2 (de) * 1999-03-17 2007-08-30 Coloplast A/S Druckempfindliche klebstoffzusammensetzung
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
DE60025019T2 (de) * 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
WO2003024427A1 (en) * 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
EP1110550B2 (en) * 1999-12-22 2007-04-04 DSM IP Assets B.V. Composition comprising ascorbic acid as a principal component and pectin
AU2001231000A1 (en) * 2000-01-19 2001-07-31 Pharmaceutical Discovery Corporation Dry powder formulations of antihistamine for nasal administration
US6228387B1 (en) * 2000-01-27 2001-05-08 Murray Borod Integrated comprehensive hemorrhoid treatment compositions and regimen
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US6368639B1 (en) * 2000-03-24 2002-04-09 Council Of Scientific And Industrial Research Herbal skin care formulation and a process for the preparation thereof
US6248360B1 (en) * 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
US6365200B1 (en) * 2000-07-19 2002-04-02 Jason C. Birnholz Topical skin sensitizer
ES2387537T3 (es) * 2000-09-13 2012-09-25 Glaxosmithkline Llc Composiciones farmacéuticas para la administración sostenida de péptidos
US6596297B2 (en) * 2000-10-30 2003-07-22 New York Blood Center, Inc. Biodegradable microbicidal vaginal barrier device
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
ES2250711T3 (es) * 2001-09-03 2006-04-16 Dsm Ip Assets B.V. Composiciones que comprenden pectina y acido ascorbico.
US20030186271A1 (en) * 2001-11-19 2003-10-02 Robin Hwang Pharmaceutical compositions in particulate form
JP2004002320A (ja) * 2002-03-04 2004-01-08 Medorekkusu:Kk 生体内で相転移する液状マトリックスおよび液状経口製剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7705135B2 (en) 1998-05-13 2010-04-27 Nanotherapeutics, Inc. Pharmaceutical compositions comprising aloe pectins, and methods for their production and use

Also Published As

Publication number Publication date
CA2537290A1 (en) 2005-03-17
CN1874679A (zh) 2006-12-06
JP2007504129A (ja) 2007-03-01
US20050084534A1 (en) 2005-04-21
EP1663111A2 (en) 2006-06-07
WO2005023176A2 (en) 2005-03-17
EA010351B1 (ru) 2008-08-29
KR20060127841A (ko) 2006-12-13
WO2005023176A3 (en) 2006-06-15
CA2537290C (en) 2013-07-09
AU2004270101A1 (en) 2005-03-17
US7494669B2 (en) 2009-02-24
EP1663111A4 (en) 2009-10-21
JP4765020B2 (ja) 2011-09-07

Similar Documents

Publication Publication Date Title
EA200600484A1 (ru) Доставка физиологических агентов in situ при помощи гелей, включающих анионные полисахариды
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
EP2322215A3 (en) Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
RU2350333C3 (ru) Применение ивермектина для лечения дерматологических расстройств
WO2007040469A3 (en) Chloroquine coupled compositions and methods for their synthesis
MY167123A (en) Conveniently implantable sustained release drug compositions
UA74443C2 (ru) Лиганды 5-нт рецептора и их применение
NO20075136L (no) Nye liposompreparater
EP1790340A3 (en) Combination chemotherapy
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
EP2626368A3 (en) Insulin-oligomer conjugates, formulations and uses thereof
MY145790A (en) Composition
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
ATE432689T1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
AR053977A1 (es) Composiciones farmaceuticas con enmascaramiento de sabor
CR8473A (es) Composicion farmaceutica de vinflunina para administracion parenteral y proceso de preparacion de dicha composicion
MX2007007099A (es) Implante formado in situ para animales.
MXPA04005420A (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1.
DE602006020666D1 (de) Methoden und Zusammensetzungen zur Beruhigung von Mund- und Nasenschleimhäuten
EA200701525A1 (ru) Фармацевтическая полимерная композиция для перорального введения тербуталина сульфата с контролируемым высвобождением
EP1759707A3 (en) Canine tumor treatment method, pharmaceutical formulation applied thereto and method of cryogenically preserving cells used therewith
TH59782A3 (th) สารผสมของกาแลนแทมีนชนิดปลดปล่อยที่มีการควบคุม
Ahmad et al. Bioadhesive Vaginal Gels of Novel Antimicrobial Combinations from Herbal Sources.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU